Kate Markham

Dr. Markham is a biochemistry scientist at Nitrome Biosciences where she is characterizing the enzymology and structural components of enzymes. Utilizing a wide variety of biophysical methods to determine protein binding and structural details as well as developing assays to study enzymology.

In her previous work with neurological proteins, Dr. Markham used multidimensional NMR and other biophysical techniques to elucidate structural information about the folding and misfolding of the prion protein as well as spectroscopic methods to determine the Ki for small molecule inhibitors to lipoxygenase-12 to initiate the development of a therapeutic for diabetes. Prior to her structural work, she performed enzymology at CytomX and in graduate school characterized novel antibodies targeting protease active sites, developed active site titration assays, developed ELISA protocols for assessments of samples in vivo models, and characterized novel protease substrates using fluorogenic peptides. As a scientist at Bioverativ/Sanofi, she was able to contribute to the writing and review of technical reports in support of IND submission, as well as perform critical experiments for such reports. She developed and characterized bioassays for the identification of pharmacodynamic biomarkers of classical and alternative complement activation. Dr. Markham holds a Ph.D. in chemistry from the University California Santa Cruz in the program for biomedical science and engineering and a BS in biochemistry from San Francisco State University.